Hans D. Menssen - Concepedia

Author

Hans D. Menssen

Also Known As

H D Menssen, H. D. Menssen, H. Menssen, H.D. Menssen, Hans D Menssen, Hans D. Menssen, Hans Dietrich Menssen, Hans Menssen, Menssen, Hans D

104

Publications

5.2K

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)ETH Zurich Philogen (Italy)Jena University Hospital University of Turin

About

Hans D. Menssen is an author at Novartis (Switzerland) specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	616
2	Immunology	9	9	475
3	Health Sciences	3	3	99
4	Cell Biology	3	3	112
5	Molecular Medicine	1	1	20

Hans D. Menssen

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia Andreas Hochhaus, Richard A. Larson, François Guilhot, New England Journal of Medicine	2017	1.2K
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes, Leukemia	2016	841
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study Andreas Hochhaus, Tamás Masszi, Francis J. Giles, Leukemia	2017	286
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib Timothy P. Hughes, Giuseppe Saglio, Hagop M. Kantarjian, Blood	2013	251
The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma Manfred Johannsen, Gianluca Spitaleri, Giuseppe Curigliano, European Journal of Cancer UrologyCancer ImmunosurveillanceGenitourinary CancerMedicineImmunology	2010	179
Expression of the oncofetal ED-B–containing fibronectin isoform in hematologic tumors enables ED-B–targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients Stefanie Sauer, Paola Anna Erba, Mario Petrini, Blood	2009	170
Effects of Long-Term Intravenous Ibandronate Therapy on Skeletal-Related Events, Survival, and Bone Resorption Markers in Patients With Advanced Multiple Myeloma Hans D. Menssen, A Sakalová, A Fontana, Journal of Clinical Oncology	2002	159
A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma Thomas Eigentler, Benjamin Weide, Filippo de Braud, Clinical Cancer Research	2011	149
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2 Christoph Schliemann, Alessandro Palumbo, Kathrin Zuberbühler, Blood	2008	146
Metastatic but not primary melanoma cell lines grow <i>in vitro</i> independently of exogenous growth factors Ulrich Rodeck, Meenhard Herlyn, Hans D. Menssen, International Journal of Cancer	1987	143

Page 1